Get the Stockscreener App
2.14
4.90%
0.10
After Hours:
2.14
Cellectar Biosciences Inc stock is traded at $2.14, with a volume of 267.13K.
It is up +4.90% in the last 24 hours and down -2.73% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
See More
Previous Close:
$2.04
Open:
$2.04
24h Volume:
267.13K
Relative Volume:
0.51
Market Cap:
$76.54M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.6446
EPS:
-3.32
Net Cash Flow:
$-30.91M
1W Performance:
+7.54%
1M Performance:
-2.73%
6M Performance:
-46.23%
1Y Performance:
-18.94%
1-Day Range:
$2.04
$2.1733
1-Week Range:
$1.90
$2.1733
52-Week Range:
$1.82
$4.45
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences (NASDAQ:CLRB) Upgraded at StockNews.com - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Upgraded to "Sell" by StockNews.com - MarketBeat
Cellectar Biosciences (NASDAQ:CLRB) Stock Quotes, Forecast and News Summary - Benzinga
Was there any good news for Cellebrite DI Ltd (CLBT) stock in the last session? - US Post News
Trust Investment Advisors Acquires Shares of 24,250 Celestica Inc. (NYSE:CLS) - MarketBeat
Cellucare Reviews (DO NOT BUY YET) Any Side Effects or Customer Complaints in 2024? - Businessday
Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily
CLS’s Stock Journey: What Investors Need to Know About Celestica, Inc.’s Performance - The InvestChronicle
Ratios Revealed: Decoding Celestica, Inc. (CLS)’s Financial Health - The Dwinnex
Celestica, Inc. (CLS) presents a great opportunity, but the stock is slightly undervalued - US Post News
Cellecor Gadgets Limted acquires 100% equity of Cellecor Foundation towards its CSR initiatives and commitments - APN News
Cellecor Gadgets shares rally 5% to hit new 52-week high; check key trigger - ET Now
Renaissance Technologies LLC Sells 12,126 Shares of Chemed Co. (NYSE:CHE) - Defense World
Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com - Defense World
Cellecor Gadgets Ltd. Acquires Full Equity of Cellecor Foundation for CSR Initiatives - IndiaCSR
Cellecor Gadgets shares update on CSR initiatives after announcing new collaborationsDetails - India.com
Cell C in big fight with oldest shareholder - MyBroadband
Cemtrex (NASDAQ:CETX) Now Covered by StockNews.com - Defense World
10:1 stock split & 585 per cent returns: Penny stock under Rs 65 to keep under radar as company acquires 100 per cent in Cellecor Foundation for CSR Activities - Dalal Street Investment Journal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CBZ, MNTX, SBT on Behalf of Shareholders - ForexTV.com
Carter's Stock Gains 10.5% In A Month: Should You Buy, Hold Or Sell? - Barchart
There is no doubt that Celldex Therapeutics Inc. (CLDX) ticks all the boxes. - SETE News
Trend Tracker for (CLS) - Stock Traders Daily
(CLDX) Investment Report - Stock Traders Daily
In the Green: Cerus Corp. (CERS) Closes at 1.97, Up/Down -4.37 from Previous Day - The Dwinnex
Creo Medical to get £25m boost from majority sale of its European business - Business Live
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA - Yahoo Finance
Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks
The CelluCare Reviews Unraveling the Truth: Is It Real or Fraud? Expert Insights Revealed! - openPR
Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com - MarketBeat
How Is The Market Feeling About Celestica? - Benzinga
A look into Cellebrite DI Ltd (CLBT)’s deeper side - SETE News
Multibagger RETURN of 526%: Cellecor Gadgets shares hit 52-week high on new partnerships - MSN
10:1 Stock Split: Multibagger Consumer Electronic Company Partners with Hello Mobiles to Expand Retail Footprint in Telangana – Stock Hits Upper Circuit Today! - Dalal Street Investment Journal
Can you now get a good deal on Celldex Therapeutics Inc.’s shares? - US Post News
Sofinnova Investments Inc. Lowers Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Small-cap stock below ₹100: SME player hits record high after strategic collaboration update - MSN
Small-Cap Sensation: Cellecor Gadgets Stock Soars to Record High After Strategic Tie-Ups in Key Markets - Share Price India News
Small-cap stock below ₹100: SME player hits record high after strategic collaboration update | Stock Market News - Mint
Deeper Dive: Understanding Celldex Therapeutics Inc. (CLDX) Through its Various Ratios - The Dwinnex
Does Cerus Corp. (CERS) offer a good opportunity for investors? - SETE News
Healthy Upside Potential: Celestica, Inc. (CLS) - SETE News
Cellebrite Shares Surge, Triggering Stock Issuance - TipRanks
Celldex Therapeutics Inc. [CLDX] Investment Appeal on the Rise - Knox Daily
Upper Circuit & 52-Week High Alert: Multibagger Penny Stock Under Rs 55, Rockets Over 500 Per Cent From 52-Week Low - Dalal Street Investment Journal
Cellebrite DI (NASDAQ:CLBT) Sets New 12-Month High at $17.48 - MarketBeat
CLBT stock soars to all-time high, reaching $17.48 - Investing.com
Is Cellebrite DI Ltd (CLBT) a good investment opportunity? - US Post News
Cerus (NASDAQ:CERS) Shares Pass Above 200 Day Moving Average of $1.97 - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Stock Passes Below 200 Day Moving Average of $2.99 - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Below 200 Day Moving Average of $2.99 - MarketBeat
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):